This webinar will provide an update on the key clinic trials in MPNs including those presented at ASH 2022
At the end of this session, participants will be able to:
-Recognize the unmet needs in the treatment of MPNs
-Identify the ongoing clinical trials in the field of MPNs
-Reflect on the future landscape of treatment of MPNs
Management of patients affected by CLL is becoming more complicated with the availability of novel treatments as monotherapy and/or in combination. The possibility of utilizing therapeutic options in a continuous fashion or with a fixed-duration schedule allows more flexibility to the caring physician to adapt to the patient's preferences but also involves the need of carefully evaluating the genetic features and the overall fitness profile of each single individuals in order to obtain the most durable control of the disease at the lowest risk of adverse events.
MARSEILLE CHANOT, PALAIS DES CONGRÈS ET DES EXPOSITIONS – SAFIM
Rond Point du Prado / 13008 Marseille, Marseilles
Explore: The latest science, research updates, workshops with the top leaders and experts in the MDS field
Exchange: Connect with colleagues from around the globe, share perspectives, experiences and ideas, and form new collaborations
Advance: The future of research and patient care is in our hands. Let us help you and your patients thrive.
The Thalassaemia International Federation (TIF) is delighted to announce the organisation of the 16th International Conference on Thalassaemia & Haemoglobinopathies & 18th TIF International Conference for Patients and Parents. The Conference is organised by TIF in collaboration with the Federation of Malaysia Thalassaemia Societies and...
Key learning objectives:
∙ Explain the mechanism of action of BCMA-targeted strategies for the treatment of relapsed/refractory multiple myeloma (RRMM)
∙ Evaluate the clinical evidence with BCMA-targeted approaches for the treatment of RRMM
∙ Discuss practical considerations, including key differences between BCMA-targeted treatments, that may inform their use in RRMM